Key clinical point: The hyperkalemia that commonly occurs in patients hospitalized for acute heart failure does not affect outcomes, but it can lead to treatment changes.
Major finding: There was a significant link between MRA dose reductions and 180-day mortality in a multivariate analysis (HR, 1.73; 95% confidence interval, 1.15-2.60; P = 0.008).
Study details: Analysis of 1,589 patients with acute heart failure and mild or moderate renal impairment from the randomized PROTECT trial.
Disclosures: Several investigators disclosed serving as advisers to and receiving honoraria and research and travel support from numerous industry members, including Abbott Vascular, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Corvia Medical, Medtronic, Merck, Myokardia, Novartis, Pfizer, Roche, Servier, and Vifor Pharma.
SOURCE: J Am Coll Cardiol HF. 2019 Oct 9. doi: 10.1016/j.jchf.2019.07.010.